Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab

Fig. 2

Kaplan-Meier survival curve of progression-free survival (PFS) and overall survival (OS). PFS (a) and OS (b) following nivolumab treatment in non-irAE group (N = 51) and irAE group (N = 14); PFS (c) and OS (d) following nivolumab treatment in non-irAE group (N = 31) and irAE group (N = 14) by landmark time (2 months)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us